Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination

J Infect. 2023 Sep;87(3):270-272. doi: 10.1016/j.jinf.2023.06.019. Epub 2023 Jun 30.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • BNT162 Vaccine*
  • COVID-19 Vaccines
  • COVID-19* / prevention & control
  • Humans
  • Long-Term Care
  • SARS-CoV-2
  • Vaccination

Substances

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • Antibodies, Viral